A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising ...
Our study found that doing these kinds of screenings on patients doesn't make any marked difference in their long-term survival rates." J. Brent Muhlestein, principal investigator of the study and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback